PEPTONIC medical (NGM:PMED) - Hisse Senedi Fiyatı, Haberler ve Analizler

PMED Stoklara Genel Bakış

A pharmaceutical company, researches, develops, and sells medical treatments and lifestyle products in the field of women's health.

Şirket hakkında

PMED temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	3/6
Temettüler	0/6

Ödüller

Risk Analizi

Hisse senetleri oldukça likit değildir

Kazançlar son 5 yılda yılda 21.8% oranında azaldı

Anlamlı bir piyasa değeri yok ( SEK92M )

Anlamlı bir geliri yok ( SEK41M )

+ 1 daha fazla risk

PEPTONIC medical AB (publ) Rakipler

CS Medica

NGM:CSMED

DKK 55.9m

AcuCort

NGM:ACUC

SEK 110.8m

Corline Biomedical

OM:CLBIO

SEK 171.9m

Double Bond Pharmaceutical International

NGM:DBP B

SEK 31.5m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti PEPTONIC medical
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	SEK 0.06
52 Haftanın En Yüksek Seviyesi	SEK 0.13
52 Haftanın En Düşük Seviyesi	SEK 0.05
Beta	0.18
11 Aylık Değişim	0%
3 Aylık Değişim	0%
1 Yıllık Değişim	-27.71%
33 Yıllık Değişim	-95.15%
5 Yıllık Değişim	-92.95%
Halka arzdan bu yana değişim	-99.43%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	PMED	SE Pharmaceuticals	SE Pazar
7D	0%	-1.5%	-1.4%
1Y	-27.7%	38.6%	20.7%

Getiri vs. Endüstri: PMED geçen yıl % 38.6 oranında getiri sağlayan Swedish Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: PMED geçen yıl % 20.7 oranında getiri sağlayan Swedish Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is PMED's price volatile compared to industry and market?
PMED volatility
PMED Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	11.1%
Market Average Movement	5.4%
10% most volatile stocks in SE Market	10.8%
10% least volatile stocks in SE Market	3.2%

İstikrarlı Hisse Senedi Fiyatı: PMED son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: PMED 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2009	32	Erik Sundquist	www.peptonicmedical.se

PEPTONIC medical AB (publ) Temel Bilgiler Özeti

PEPTONIC medical'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
PMED temel i̇stati̇sti̇kler
Piyasa değeri	SEK 92.09m
Kazançlar(TTM)	-SEK 31.00m
Gelir(TTM)	SEK 40.52m

2.3x

P/S Oranı

-3.0x

F/K Oranı

PMED aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
PMED gelir tablosu (TTM)
Gelir	SEK 40.52m
Gelir Maliyeti	SEK 20.53m
Brüt Kâr	SEK 20.00m
Diğer Giderler	SEK 51.00m
Kazançlar	-SEK 31.00m

Son Raporlanan Kazançlar

Sep 30, 2023

Sonraki Kazanç Tarihi

May 07, 2024

Hisse başına kazanç (EPS)	-0.02
Brüt Marj	49.35%
Net Kâr Marjı	-76.50%
Borç/Özkaynak Oranı	6.7%

PMED uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

PMED Stoklara Genel Bakış

Ödüller

Risk Analizi

PEPTONIC medical AB (publ) Rakipler

NGM:CSMED

DKK 55.9m

NGM:ACUC

SEK 110.8m

OM:CLBIO

SEK 171.9m

NGM:DBP B

SEK 31.5m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

PEPTONIC medical AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

PEPTONIC medical AB (publ) to Report Q2, 2024 Results on Aug 13, 2024

Peptonic Medical AB Granted Patent in Australia: Vernivia Secures Exclusivity Until 2038

Peptonic Medical AB Grants Patent in Europe for Relief of Provoked Vulvodynia in Women, Product Ready for Launch

PEPTONIC medical AB (publ) Announces Chief Financial Officer Changes

PEPTONIC medical AB (publ), Annual General Meeting, May 21, 2024

Recent updates

PEPTONIC medical AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

PEPTONIC medical AB (publ) to Report Q2, 2024 Results on Aug 13, 2024

Peptonic Medical AB Granted Patent in Australia: Vernivia Secures Exclusivity Until 2038

Peptonic Medical AB Grants Patent in Europe for Relief of Provoked Vulvodynia in Women, Product Ready for Launch

PEPTONIC medical AB (publ) Announces Chief Financial Officer Changes

PEPTONIC medical AB (publ), Annual General Meeting, May 21, 2024

PEPTONIC medical AB (publ) to Report Q1, 2024 Results on May 07, 2024

PEPTONIC medical AB (publ) Announces Resignation of Albert Lindgren as CFO

Peptonic Medical AB (Publ) Announces Patented Apoteket Offering in 293 Apoteket Stores

Third quarter 2023 earnings released

Second quarter 2023 earnings released

Peptonic Medical AB (Publ) Appoints Albert Lindgren as Chief Financial Officer, Effective from October 21, 2023

District Court Rejects the Claim for A Corporate Fine and Acquits All in Insider Case Against Peptonic Medical AB (Publ)

PEPTONIC medical AB (publ) (NGM:PMED) signed a letter of intent to acquire Pharmiva AB (publ) (OM : PHARM) for SEK 15.2 million.

Pharmiva AB (publ) (OM:PHARM) entered in the letter of intent to acquire PEPTONIC medical AB (publ) (NGM:PMED).

Peptonic Medical AB (Publ) Announces the Application to Patent Its Intimate Cleaner in US to Be Approved on June 20, 2023

Less than half of directors are independent

First quarter 2023 earnings released

Full year 2022 earnings released: kr0.15 loss per share (vs kr0.39 loss in FY 2021)

High number of new and inexperienced directors

PEPTONIC medical AB (publ) Ongoing Applications for the Intimate Wash and for the Treatment of Fungal Infection Has Received Positive Statements from the International Review

Peptonic Medical AB (Publ) Announces Vagivital® Al Self-Test for Amniotic Fluid Leakage Detection Is Now Commercially Available for Sale in Its Own Online Store

Peptonic Medical's Ongoing Application for Vestibulitis Patent Receives Positive Opinion from the International Review

Second quarter 2022 earnings released: kr0.037 loss per share (vs kr0.064 loss in 2Q 2021)

High number of new and inexperienced directors

First quarter 2022 earnings released

No independent directors

Hans von Celsing, Leni Ekendahl, Marianne Östlund and Anna Tenstam Declines Re-Election to the Board of Directors of PEPTONIC medical AB (publ)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

PEPTONIC medical AB (publ) to Report Q3, 2022 Results on Nov 10, 2022

Peptonic Medical Introduces the Vagivital Range of Products to the US Market

Third quarter 2021 earnings released

PEPTONIC Initiates Non-Exclusive Negotiations Regarding a Possible Acquisition of All Assets in CommonSense Ltd (Israel)

Second quarter 2021 earnings released: kr0.064 loss per share (vs kr0.051 loss in 2Q 2020)

Peptonic Medical Gets Approval to Start a Clinical Trial for the Treatment of Vaginal Fungal Infections with an Adapted Version of VagiVital AktivGel

Peptonic Medical AB (Publ) Announces Latest Clinical Study with Vagivita

Peptonic Medical (publ) to Launch New Innovative Intimate Care Range Under Lunette Brand, Bringing Special Nordic Ingredients Down There

First quarter 2021 earnings released

New 90-day low: kr1.55

PEPTONIC medical AB (publ), Annual General Meeting, Jun 09, 2021

New 90-day low: kr1.60

Chief Financial Officer recently sold kr84k worth of stock

New 90-day low: kr1.68

Third quarter 2020 earnings released: kr0.041 loss per share

Peptonic to Launch the Self-Test Under the VagiVital® Brand

New 90-day low: kr1.98

Peptonic Medical AB Files Patent Application for the Treatment of Fungal Infections and Bacterial Vaginosis

New 90-day high - kr2.38

Earnings released

New 90-day high - kr2.24

PEPTONIC medical AB (publ) (NGM:PMED) exercised the option to acquire remaining 26.67% stake in Lune Group Oy Ltd for €1.2 million.